

Engineering liver model using CELLBLOKS®: a novel approach to in-vitro pre-clinical drug screening M. R. Siddique, Anais Makos, Ahtasham Raza, Imran Patel & Valon Llabjani Revivocell Limited, Sci-Tech Daresbury, Keckwick Lane, Daresbury, WarringotnWA4 4AD, valon@revivocell.com

Introduction

Drug induced liver injury (DILI) continues to be the leading cause of attrition during drug development in all phases of clinical trials as well as number one cause of post-market drug withdrawal, accounting for 20-40 % of all cases (1).

Current preclinical *in-vivo* animal models often fail to predict drug adverse reactions in humans (hepatotoxicity by 50--60%) due to substantial differences of drug metabolising enzymes between animals and humans, and existing *in-vitro* cell culture models do not represent complex organotypic conditions (2,3).

Typically cells are grown in 2-D surfaces and in isolation containing only one cell type. In these environments cells become flattered, lack cell-cell communication vital for replicating biological relevance and behave in aberrant fashion

The study demonstrate how a novel platform, CELLBLOKS® aims to improve research in drug discovery and reduce animal testing.



CELLBLOKS® introduction

A first of its kind modular "plug and play" cell culture platform: cell-cell communication studies made easy





Achieve better representation of different Organtype communications

- Circulatory Pods can be used to simulate organs in systematic circulation
- Barrier Pods organs representing biological barriers
- Blank Pods are also available for isolating cell cultures during experimentation.



Modelling multiple cell-type liver archetype

Figure I. Liver model set up on CELLBLOKS® platform in non-contact vs. contact co-culture standard format.

- screening.
- 2017;2461694 (2000).
- Toxicol. Pharmacol. 2000;32.

This research was funded by Innovate UK.

Results

• Overall Albumin and Urea production measured in HepG2 cells was significantly higher in non-contact CELLBLOKS platform compared to contact cell cultures in standard 12 Well plate leading to up to three times increase in production.

 Both Urea and Albumin production remained higher in CELLBLOKS® compared to well plate format over the duration of 12 days where protein production plateaued in both platforms

• In general Albumin and Unreal production was higher when HepG2 cells were in co-cultures compared monocultures in CELLBLOKS®. However, in contact 12-WP format when HepG2 cells were cultured with either HUVEC and NIH/3T3 cells hepatic function either remained unchanged or was inhibited.

Discussion

• CELLBLOKS® is a novel cell culture platform where cell-cell in-vitro interaction studies can be easily set up and analysed as the platform is compatible with current imaging and analysis techniques.

• The data from this study shows that hepatic function is significantly improved in non-contact co-cultures compared to mono-cultures indicating the need incorporation of co-cultures in DILI drug

• CELLBLOKS® aims to increase the success rate of drug screening by prioritising candidates that are likely to succeed and eliminates those likely to fail in human clinical trials, particularly in Phase I and at the same time reducing the reliance on animal testing.

References

. Almario E.E., Borlak J., Suzuki A., Chen M. Drug-induced liver injury. BioMed Res. Int.

2. Ison H et al., Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul.

3. L Kuna et al., Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Prospectives. Current Drug Metabolism. 2018:19:10.

email@university.edu